FDA's Anti-Infective Drugs Advisory Committee
July 18-19 agenda includes a review of Abbott's NDA (No. 50-662) for clarithromycin, an oral, second generation broad-spectrum macrolide antibiotic for lower respiratory tract, community-acquired upper respiratory tract, and skin and soft tissue infections. At a May analysts meeting, Abbott Chairman Duane Burnham noted that clarithromycin has a broader spectrum than erythromycin and higher potency. The advisory committee will also review the NDA (No. 50-670) for Pfizer's oral, once-daily, macrolide antibiotic Zithromax (azithromycin) for bacterial infections including sexually transmitted diseases, upper and lower respiratory tract infections, skin and skin structure infections and pediatric infections. Pfizer, which filed the NDA in April 1990, has claimed that clarithromycin "does not share the remarkable targeted delivery and pharmacokinetic properties of azithromycin." The NDAs will be discussed on the first day of the meeting, which begins at 8:30 a.m. in conference rooms D & E at FDA's Parklawn BUilding. The second day is set aside for closed committee deliberations on pending NDAs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth